SCHEMBL22012971

SCHEMBL22012971

CCCC(CC)N(C)C(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.37
CA12 O43570 2/20 0.37
CA14 Q9ULX7 2/20 0.37
CA2 P00918 2/20 0.37
CTSK P43235 5/20 0.34
CTSS P25774 2/20 0.34
HDAC6 Q9UBN7 2/20 0.33
CA7 P43166 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
MMP13 P45452 1/20 0.31
AAK1 Q2M2I8 1/20 0.31
MEN1 O00255 1/20 0.30
GAA P10253 1/20 0.30
KMT2A Q03164 1/20 0.30
NFKB1 P19838 1/20 0.30
NFKB2 Q00653 1/20 0.30
RELA Q04206 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23564665 0.89 HDAC6 (0.36) CA1CA12CA14CA2CTSK
SCHEMBL29852060 0.87 CA2 (0.38) CA2CTSKHDAC6HDAC1HDAC2
SCHEMBL30376800 0.87 CA2 (0.38) CA2CTSKHDAC6HDAC1HDAC2
SCHEMBL25123300 0.86 AAK1 (0.34) CA1CA12CA14CA2HDAC6
SCHEMBL13999424 0.85 AAK1 (0.39) CA1CA12CA14CA2CTSK
SCHEMBL17571449 0.84 HDAC6 (0.33) CA1CA12CA14CA2CTSK
SCHEMBL9606667 0.82 HDAC6 (0.32) CA1CA12CA14CA2HDAC6
SCHEMBL16281192 0.82 HDAC6 (0.33) HDAC6HDAC1HDAC2MMP13AAK1
SCHEMBL6756534 0.81 CA14 (0.39) CA1CA12CA14CA2CTSK
SCHEMBL24881082 0.80 CA1 (0.38) CA1CA12CA14CA2CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3700911-B1 NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2023-09-06 EP disclosed
WO-2020102576-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS INFLAMMASOME RESEARCH, INC. (US) 2020-05-22 WO disclosed